Plasma neuropeptide Y in patients with major depressive disorder

Neuroscience Letters

Volumn 216, Issue 1, 1996, Pages 57-60

  Hashimoto, Hiroshi ^a   Onishi, Hiroshi ^a   Koide, Seiji ^a   Kai, Toshihiro ^b   Yamagami, Sakae ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

Depression; High performance liquid chromatography; Major depressive disorder; Neuropeptide; Neuropeptide Y; Plasma; Radioimmunoassay analysis

Indexed keywords

NEUROPEPTIDE Y;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0030595309     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3940(96)13008-1     Document Type: Article

References (25)

1. [1] Åkesson, A. and Ekman, R., Gastrointestinal regulatory peptides in systemic sclerosis, Arthritis Rheum., 36 (1993) 698-703.
2. [2] Allen, J.M., Adrian, T.E., Polak, J.M. and Bloom, S.R., Neuropeptide Y (NPY) in the adrenal gland, J. Autonomic Nerv. Syst., 9 (1983) 559-563.
3. [3] American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn., APA, Washington DC, 1994.
4. [4] Angwin, P. and Barchas, J.D., Analysis of peptides in tissue and plasma, J. Chromatogr., 231 (1982) 173-177.
5. [5] Biggins, J.A., McDermott, J.R., Smith, A.I., Candy, J.M., Perry, R.H., Bateman, D.E. and Edwardson, J.A., Chromatographic characterization of neuropeptides in post mortem human brain, J. Neurol. Sci., 66 (1984) 47-58.
6. [6] De Quidt, M.E. and Emson, P.C., Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system. II. Immunohistochemical analysis, Neuroscience, 18 (1986) 545-618.
7. [7] Edvinsson, L., Ekman, R. and Thulin, T., Increased plasma levels of neuropeptide Y-like immunoreactivity and catecholamines in severe hypertension remain after treatment to normotension in man, Regul. Pept., 32 (1991) 279-287.
8. [8] Everitt, B.J., Hökfelt, T., Terenius, L., Tatemoto, K., Mutt, V. and Goldstein, M., Differential co-existence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat, Neuroscience, 11 (1984) 443-462.
9. [9] Fridland, G.H. and Desiderio. D.M., Measurement of opioid peptides with combinations of reversed phase high performance liquid chromatography, radioimmunoassay, radioreceptorassay, and mass spectrometry. Life Sci., 41 (1987) 809-812.
10. [10] Halliday, G.M., Li, Y.W., Oliver, J.R., Joh, T.H., Cotton, R.G.H., Howe, P.R.C., Geffen, L.B. and Blessing, W.W., The distribution of neuropeptide Y-like immunoreactive neurons in the human medulla oblongata, Neuroscience, 26 (1988) 179-191.
11. [11] Hamilton, M., Development of a rating scale for primary depressive illness, Br. J. Soc. Clin. Psychol., 6 (1967) 278-296.
12. [12] Heilig, M., Wahlestedt, C., Ekman, R. and Widerlöv, E., Antidepressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain, Eur. J. Pharmacol., 147 (1988) 465-467.
13. [13] Heilig, M. and Widerlöv, E., Neuropeptide Y: an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. Acta Psychiatr. Scand., 82 (1990) 95-114.
14. [14] Hong, J.-S., Yoshikawa, K. and Hendren, R.W., Measurement of β-endorphin and enkephalins in biological tissues and fluids. In P.M. Conn (Ed.), Methods in Enzymology, Vol. 103, Academic Press, New York, 1983, pp. 547-564.
15. [15] Irwin, M., Brown, M., Patterson, T., Hauger, R., Mascovich, A. and Grant, I., Neuropeptide Y and natural killer cell activity: findings in depression and Alzhcimer caregiver stress, FASEB J., 5 (1991) 3100-3107.
16. [16] Koide, S., Onishi, H., Katayama, M. and Yamagami, S., Metabolic profile of opioid peptides differs in the hippocampus and striatum of seizure-susceptible El mice, Neurochem. Res., 20 (1995) 279-283.
17. [17] Nemeroff, C.B., Bissette, G., Akil, H. and Fink, M., Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy, corticotrophin-releasing factor, β-endorprin and somatostatin, Br. J. Psychiatry, 158 (1991) 59-63.
18. [18] Rubinow, D.R., Gold, P.W., Post, R.M., Ballenger, J.C., Cowdry, R., Bollinger, J. and Reichlin, S., CSF somatostatin in affective illness, Arch. Gen. Psychiatry, 40 (1983) 409-412.
19. [19] Sundler, F., Håkanson, R., Ekblad, E., Uddman, R. and Wahlestedt, C., Neuropeptide Y in the peripheral adrenergic and enteric nervous systems. Int. Rev. Cytol., 102 (1986) 243-269.
20. [20] Tabarin, A., Cassiède, P., Minot, A.P., Cuber, J.C., Roger, P. and Ducassou, D., Heterogeneity of neuropeptide Y immunoreactivity in patients with pheochromocytoma: influence on the diagnostic power of measuring plasma NPY using antisera with different specificities, Acta Endocrinol., 128 (1993) 243-250.
21. [21] Tatemoto, K., Carlquist, M. and Mutt, V., Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide, Nature, 296 (1982) 659-660.
22. [22] Tinsley, P.W., Fridland, G.H., Killmar, J.T. and Desiderio, D.M., Purification, characterization, and localization of neuropeptides in the cornea, Peptides, 9 (1989) 1373-1379.
23. [23] Wahlestedt, C., Blendy, J.A., Kellar, K.J., Heilig, M., Widerlöv, E. and Ekman, R., Electroconvulsive shocks increase the concentration of neocortical and hippocampal neuropeptide Y (NPY)-like immunoreactivity in the rat, Brain Res., 507 (1990) 65-68.
24. [24] Widdowson, P.S., Ordway, G.A. and Halaris, A.E., Reduced neuropeptide Y concentrations in suicide brain, J. Neurochem., 59 (1992) 73-80.
25. [25] Widerlöv, E., Lindström, L.H., Wahlestedt, C. and Ekman, R., Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively, J. Psychiatr. Res., 22 (1988) 69-79.